NTD Eurofins – A History of Innovation
Since its inception, NTD Eurofins has demonstrated a history of innovation, beginning with its work in neural tube defect research and continuing to where it stands today, at the forefront of prenatal care and genetic screening.
NTD Eurofins was the first to introduce;
Today, NTD Eurofins provides first and second trimester prenatal screening, genetic carrier screening, and hereditary cancer screening services to universities, medical centers, hospitals, laboratories, obstetricians and maternal fetal medicine (MFM) specialists worldwide through an accredited facility owned and operated by Eurofins Scientific. With an unwavering commitment to quality, combined with industry-leading best practices, NTD Eurofins remains at the forefront of research and innovation in maternal fetal healthcare industry.
Over Three Decades of Prenatal Screening
First AFP screening for neural tube defects introduced in the United States of America by James N. Macri.
NTD Labs was incorporated by Dr. Macri as a prenatal screening and research laboratory.
Discovered free beta hCG as the most discriminatory biochemical marker for Down syndrome.
Large multi-center study published in the New England Journal of Medicine validates the advantages of the free Beta hCG/PAPP-A/NT protocol.
Fetal nasal bone assessment protocol introduced as part of NTD Labs first trimester Down syndrome screening protocol.
NTD introduces web portal to facilitate Instant Risk Assessment reporting within the Down syndrome screening protocol.